Arrowhead Research | ARWR

Stock Price
29.08
Daily Change
1.08 3.86%
Monthly
78.30%
Yearly
30.87%
Q3 Forecast
28.84

Peers Price Chg Day Year Date
Agios Pharmaceuticals 36.01 -0.12 -0.33% -16.80% Sep/05
Alnylam Pharmaceuticals 452.00 -1.54 -0.34% 83.16% Sep/05
Arrowhead Research 29.08 1.08 3.86% 30.87% Sep/05
Incyte 86.64 1.20 1.40% 41.43% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Ligand Pharmaceuticals 166.75 -0.99 -0.59% 64.87% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Ultragenyx Pharmaceutical 31.82 0.54 1.73% -42.40% Sep/05
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
TG Therapeutics 32.21 0.32 1.00% 46.21% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05
Xencor 8.55 0.18 2.15% -47.16% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05
US400 3297 16.31 0.50% 12.16% Sep/05

Arrowhead Research traded at $29.08 this Friday September 5th, increasing $1.08 or 3.86 percent since the previous trading session. Looking back, over the last four weeks, Arrowhead Research gained 78.30 percent. Over the last 12 months, its price rose by 30.87 percent. Looking ahead, we forecast Arrowhead Research to be priced at 28.84 by the end of this quarter and at 28.13 in one year, according to Trading Economics global macro models projections and analysts expectations.

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.